For example, DCX is a differentiation-based treatment in vivo for glioma, where DCX induces terminal differentiation of glioma cells via a DCX/GFAP (glial fibrillary acidic protein) pathway (Santra et al., 2010). The gene discussed is GFAP; the disease is central nervous system cancer.